Novo's obesity business and Chinese challenges will be examined closely, says analyst
A new insulin supply model in China is expected to affect sales next year, and this challenge combined with Novo Nordisk's sales figures for obesity drugs will be ABG Sundal Collier's main focus when the Danish pharmaceutical company releases its financial report tomorrow.
BY MARKETWIRE, TRANSLATED BY DANIEL PEDERSEN
Novo Nordisk's obesity business and the insulin sales prospects in China could take center stage when the Danish pharmaceutical company releases its quarterly report Wednesday morning.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk upgrades guidance
For subscribers
